CVR 39119374Private limited company (ApS)Forskning og eksperimentel udvikling inden for naturvidenskab og teknik (721000)København VFounded 28 Nov 2017
Compiled by Dandex from the Danish Business Registry (CVR, datacvr.virk.dk), Erhvervsstyrelsen, and annual reports filed in XBRL. Values marked Dandex estimate are computed by Dandex from that data, not registered.
Dandex is Danish Company Data. Connect it once and ask about Anpartsselskabet af 21.08.2026, or any Danish company, from your assistant, the API or the command line. Answers come from the current record: owners and the ownership network, financials year by year, and the latest registered changes.
Set up DandexEmployees
7
CVR, 2023
Gross profit
-1K
DKK, annual report 2025
Result
+48K
DKK, annual report 2025
Equity
807K
DKK, annual report 2025
NOVO NORDISK A/SCVR 24256790, 100% of capital and votes, since 29 Aug 2023
Rikke Ryttergaard Winstrøm Andersenuntil 21 Aug 2026
CVR 24256790100% of capital and votessince 29 Aug 2023
Holders of 5% or more, from the owner register. CVR records shares in bands, not exact figures.
CVR 3814753615% to under 20% of capital and votesnotified 29 Jun 202328 Nov 2017 to 29 Jun 2023
CVR 3911537925% to under 33.3% of capital and votesnotified 29 Jun 202328 Nov 2017 to 29 Jun 2023
CVR 3911544125% to under 33.3% of capital and votesnotified 29 Jun 202328 Nov 2017 to 29 Jun 2023
CVR 3911547625% to under 33.3% of capital and votesnotified 29 Jun 202328 Nov 2017 to 29 Jun 2023
CVR 4415222390% to under 100% of capital and votesnotified 29 Aug 202329 Jun 2023 to 29 Aug 2023
Ultimate controller
CVR 10582989Commercial foundation (erhvervsdrivende fond)
Holds 100% of capital and votes in Novo Holdings A/S, since 16 Oct 1999
Holding company
CVR 24257630Public limited company (A/S)
Holds 25% to under 33.3% of capital and 66.7% to under 90% of votes in NOVO NORDISK A/S, since 13 Nov 2000
Holding company
CVR 24256790Public limited company (A/S)
Holds 100% of capital and votes in Anpartsselskabet af 21.08.2026, since 29 Aug 2023
This company
Anpartsselskabet af 21.08.2026
CVR 39119374
Decided by Dandex with fixed rules from CVR and the filed annual reports, and for the auditor's report, the business model and the revenue model a calibrated decision model reading the report's text and the purpose clause, not registered by the company. Each label links to its definition.
CVR records founders at incorporation. It does not record whether they are alive or still involved.
28 Nov 2017 to 13 Nov 2026.
Jun 2023, monthly: 7 employees, 4 FTE
Arrow keys move through the periods, Home and End go to the first and the latest, Escape returns to the latest.
| Period | Oct 2018 | Nov 2018 | Dec 2018 | Jan 2019 | Feb 2019 | Mar 2019 | Apr 2019 | May 2019 | Jun 2019 | Jul 2019 | Aug 2019 | Sep 2019 | Oct 2019 | Nov 2019 | Dec 2019 | Jan 2020 | Feb 2020 | Mar 2020 | Apr 2020 | May 2020 | Jun 2020 | Jul 2020 | Aug 2020 | Sep 2020 | Oct 2020 | Nov 2020 | Dec 2020 | Jan 2021 | Feb 2021 | Mar 2021 | Apr 2021 | May 2021 | Jun 2021 | Jul 2021 | Aug 2021 | Sep 2021 | Oct 2021 | Nov 2021 | Dec 2021 | Jan 2022 | Feb 2022 | Mar 2022 | Apr 2022 | May 2022 | Jun 2022 | Jul 2022 | Aug 2022 | Sep 2022 | Oct 2022 | Nov 2022 | Dec 2022 | Jan 2023 | Feb 2023 | Mar 2023 | Apr 2023 | May 2023 | Jun 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Employees | 5 | 7 | 6 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 10 | 9 | 10 | 10 | 10 | 9 | 9 | 8 | 8 | 8 | 8 | 8 | 8 | 7 | 7 | 7 | 7 | 7 | 7 | 7 | 7 | 7 | 7 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 6 | 6 | 6 | 6 | 6 | 7 |
| FTE | 2 | 4 | 4 | 6 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 6 | 5 | 6 | 6 | 6 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 4 | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 4 | 5 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 5 | 4 | 4 |
| Series | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly |
The legal entity's own headcount as CVR records it, not the annual report's average, which may cover a group. Monthly Oct 2018 to Jun 2023.
CVR changed its monthly method in Oct 2019, so a step at that month need not be real.
Latest Jun 2023, published 21 Aug 2023. Source: CVR employment series (Årsbeskæftigelse, Kvartalsbeskæftigelse, Månedsbeskæftigelse).
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Gross profit | 0 | 379 | Not reported | -38 | -1 |
| Operating profit | -7,384 | -7,803 | +514,764 | Not reported | Not reported |
| Result for the year | -6,196 | -8,830 | +395,475 | +6,174 | +48 |
| Equity | 2,941 | -5,889 | 405,585 | 6,759 | 807 |
| Total assets | 10,693 | 7,777 | 516,988 | 8,506 | 833 |
| Employees (average) | 3 | 4 | 2 | 0 | 0 |
| Credit metrics (Dandex calculations) | |||||
| Gross profit growth (vækst i bruttofortjeneste) | -100% | n.m.note 1 | Not reportednote 2 | -100% | n.m.note 1 |
| EBITDA | -6,694 | -6,282 | Not reportednote 3 | Not reportednote 3 | Not reportednote 3 |
| EBITDA / gross profit (EBITDA i procent af bruttofortjenesten)Pro: EBITDA / gross profit (EBITDA i procent af bruttofortjenesten) is in the Pro plan, see pricingEBITDA as a share of gross profit. | Pro: EBITDA / gross profit (EBITDA i procent af bruttofortjenesten) is in the Pro plan, see pricingEBITDA as a share of gross profit. | ||||
| Employee growth (vækst i antal ansatte) | -40% | 33.3% | -50% | -100% | n.m.note 1 |
| Net interest-bearing debt (NIBD, nettorentebærende gæld)Pro: Net interest-bearing debt (NIBD, nettorentebærende gæld) is in the Pro plan, see pricingInterest-bearing debt less cash and current securities; negative is net cash. | Pro: Net interest-bearing debt (NIBD, nettorentebærende gæld) is in the Pro plan, see pricingInterest-bearing debt less cash and current securities; negative is net cash. | ||||
| Gearing, NIBD / EBITDAPro: Gearing, NIBD / EBITDA is in the Pro plan, see pricingNet interest-bearing debt over EBITDA: the years of earnings the debt takes. | Pro: Gearing, NIBD / EBITDA is in the Pro plan, see pricingNet interest-bearing debt over EBITDA: the years of earnings the debt takes. | ||||
| Interest coverage (rentedækning)Pro: Interest coverage (rentedækning) is in the Pro plan, see pricingEBIT over finance expenses: how many times earnings cover the interest. | Pro: Interest coverage (rentedækning) is in the Pro plan, see pricingEBIT over finance expenses: how many times earnings cover the interest. | ||||
| Adjusted equity ratio (justeret soliditetsgrad)Pro: Adjusted equity ratio (justeret soliditetsgrad) is in the Pro plan, see pricingAdjusted equity as a share of total assets on the same basis. | Pro: Adjusted equity ratio (justeret soliditetsgrad) is in the Pro plan, see pricingAdjusted equity as a share of total assets on the same basis. | ||||
| ROIC (afkast af investeret kapital)Pro: ROIC (afkast af investeret kapital) is in the Pro plan, see pricingReturn on invested capital: EBIT after tax over equity plus net debt. | Pro: ROIC (afkast af investeret kapital) is in the Pro plan, see pricingReturn on invested capital: EBIT after tax over equity plus net debt. | ||||
| Capex (investeringer i anlægsaktiver) | 0note 4 | 0note 4 | Not reportednote 5 | Not reportednote 5 | Not reportednote 5 |
| Capex % of sales (investeringer i procent af omsætningen)Pro: Capex % of sales (investeringer i procent af omsætningen) is in the Pro plan, see pricingCapex as a share of revenue. | Pro: Capex % of sales (investeringer i procent af omsætningen) is in the Pro plan, see pricingCapex as a share of revenue. | ||||
| FCFF / EBITDA (pengestrømskonvertering)Pro: FCFF / EBITDA (pengestrømskonvertering) is in the Pro plan, see pricingFree cash flow to the firm as a share of EBITDA. | Pro: FCFF / EBITDA (pengestrømskonvertering) is in the Pro plan, see pricingFree cash flow to the firm as a share of EBITDA. | ||||
DKK thousands. Annual reports via XBRL. Employees are the annual report's average and may cover a group.
Credit metrics are Dandex calculations from the filed figures, not filed values; estimates are in grey with a note. Ratios are percentages. Gearing and interest coverage are multiples. Rows marked Pro hold a value in the Pro plan. Definitions. Revenue-based rows are empty: the company reports gross profit only (bruttofortjeneste), which class B filers may.
Annual report 2025
1 Jan 2025 to 31 Dec 2025, published 11 Jun 2026
Annual report 2024
1 Jan 2024 to 31 Dec 2024, published 18 Jun 2025
Annual report 2023
1 Jan 2023 to 31 Dec 2023, published 28 Jun 2024
Annual report 2022
1 Jan 2022 to 31 Dec 2022, published 14 Jun 2023
Annual report 2021
1 Jan 2021 to 31 Dec 2021, published 13 Jun 2022
Pro: Signals (signaler) are in the Pro plan, see pricingChanges worth a look, raised from the registry and new annual reports.
New leadership (nyt lederskab), New company (ny virksomhed), Ownership change (ejerskifte), Relocation (flytning), Growth surge (vækstspurt), Headcount decline (nedgang i ansatte), Restructuring (omstrukturering), Industry change (brancheskift), Board change (bestyrelsesændring), Dissolution (ophør), Distress warning (risikoadvarsel), Fund investment (fondsinvestering), Fund exit (fondsexit), Fund board seat (fondsbestyrelsespost).
The rows marked Pro on this page hold values in the Pro plan. For Anpartsselskabet af 21.08.2026, that is:
Have Pro? Sign in to see the values on this page.
Each registered value from the day it took effect, newest first.
Demerger (spaltning), as the demerged company (indskydende selskab)
From CVR, read 13 Nov 2026. Text such as the signing rule and purpose is shown as registered.
From CVR, read 13 Nov 2026. A change is counted each time the registry records a new value, so a corrected address or an audit firm under a new entity counts too.
10 registrations, newest first. As published by Erhvervsstyrelsen, in Danish, with people's street addresses cut to postcode and city.
Likvidation vedtaget 21.08.2026
Vedtægter ændret: 21.08.2026
Ny adresse: c/o Gorrissen Federspiel, Axeltorv 2, 1609 København V
Ny kommune: København
Likvidatorer:
Tiltrådte:
Anders Ørjan Jensen, 1609 København V, den 21.08.2026.
Bestyrelse:
Fratrådte:
Kristine Aachmann Bethe, den 21.08.2026, Peter Bøggild, (formand), den 21.08.2026.
Direktion:
Fratrådte:
Rikke Ryttergaard Winstrøm Andersen, (adm. dir), den 21.08.2026.
Selskabet tegnes af likvidator.
Virksomhedens kreditorer opfordres til at anmelde deres krav til likvidator. Krav skal anmeldes senest tre måneder fra dags dato.
Vedtægter ændret: 21.08.2026
Nyt navn: Anpartsselskabet af 21.08.2026
Vedtægter ændret: 29.05.2026
Revision:
Fratrådte:
EY Godkendt Revisionspartnerselskab, den 29.05.2026.
Direktion:
Fratrådte:
Trine Haastrup, den 03.12.2025.
Tiltrådte:
Rikke Ryttergaard Andersen, (adm. dir), den 03.12.2025.
Vedtægter ændret: 29.08.2023
Nyt navn: Novo Nordisk Research Center Gladsaxe ApS
Ny adresse: Novo Alle 1, 2880 Bagsværd
Ny kommune: Gladsaxe
Bestyrelse:
Fratrådte:
Casper Tind Hansen, den 29.08.2023, Klaus Christian Schollmeier, (formand), den 29.08.2023.
Tiltrådte:
Kristine Aachmann Bethe, den 29.08.2023, Peter Bøggild, (formand), den 29.08.2023.
Direktion:
Fratrådte:
Casper Tind Hansen, (adm. dir), den 29.08.2023, Jakob Bondo Hansen, den 29.08.2023.
Tiltrådte:
Trine Haastrup, den 29.08.2023.
Selskabet tegnes af 2 bestyrelsesmedlemmer i forening eller af et bestyrelsesmedlem i forening med en direktør.
Formål ændret: Selskabets formål er at udføre forskning, udvikling og støtte kliniske forsøg af farmaceutiske produkter og at markedsføre, promovere, sælge og distribuere farmaceutiske og medicinske produkter samt enhver anden aktivitet i forbindelse hermed. Endvidere er selskabets formål at understøtte Novo Nordisk A/S' farmaceutiske aktiviteter. Selskabet bestræber sig på at udføre sine aktiviteter på en økonomisk, miljømæssig og socialt ansvarlig måde.
Erhvervsstyrelsen har modtaget oplysning om, at der er truffet beslutning om nedenstående spaltning. Kapitalejerne har i enighed besluttet, at der ikke skal udarbejdes en spaltningsplan. Der er endvidere modtaget erklæring fra vurderingsmændene om, at kreditorerne i de deltagende virksomheder må antages at være tilstrækkeligt sikrede efter spaltningen.
Aktiver og gæld er overdraget til CVR-nummer 44172410 Embark Laboratories ApS.
Vedtægter ændret: 09.08.2021
Bestyrelse:
Tiltrådte:
Casper Tind Hansen, den 09.08.2021, Klaus Christian Schollmeier, (formand), den 09.08.2021.
Direktion:
Tiltrådte:
Jakob Bondo Hansen, den 09.08.2021.
Selskabet tegnes af den samlede Bestyrelse, af to Bestyrelsesmedlemmer i forening, af Bestyrelsesformanden iforening med en Direktør, eller af to Direktører i forening.
Formål ændret: Selskabets formål er at drive forskningsvirksomhed rettet mod udvikling af lægemidler til behandling af metabolismerelaterede sygdomme, og/eller at udføre aktiviteter, der er forbundet hermed.
Revision:
Tiltrådte:
CVR-NR. 30700228 ERNST & YOUNG Godkendt Revisionspartnerselskab, Osvald Helmuths Vej 4, 2000 Frederiksberg, den 21.05.2019.
Virksomheden er omregistreret fra Iværksætterselskab til Anpartsselskab
Vedtægter ændret: 15.08.2018
Nyt navn: Embark Biotech ApS
Kapitalforhøjelsen er besluttet den 15.08.2018.
kr. 50.000,00, indbetalt kontant, kurs 100,00. kr. 515,00, indbetalt kontant, kurs 108,00.
Kapitalen udgør herefter kr. 51.515,00.
Stiftelsesdato: 28.11.2017.
Virkningsdato: 28.11.2017.
Seneste vedtægtsdato: 28.11.2017.
Kapital:
kr. 1.000,00.
Kapitalklasser: Nej
Indbetalingsmåde: Indbetalt kontant kr. 1.000,00 til kurs 500,00, fuldt indbetalt.
Stifter:
CVR-NR. 38147536 CTH Holding Invest ApS, Vangehusvej 17, 2100 København Ø, den 28.11.2017.
Direktion:
Casper Tind Hansen (adm. dir), den 28.11.2017.
Selskabet tegnes af en direktør alene, eller af hele direktionen i forening..
Første regnskabsår:
28.11.2017 - 31.12.2018.
Regnskabsår:
01.01 - 31.12.
Formål:
Selskabets formål er at drive forsknings-virksomhed rettet mod udvikling af lægemidler til behandling af fedme og fedmerelaterede sygdomme, herunder diabetes, diabetes-relaterede metaboliske sygdomme, og/eller at udføre aktiviteter, der er forbundet hermed.
1 registered in CVR.
P-number 1023071890Axeltorv 2, 1609 København V